Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs

Molecules

Volumn 14, Issue 6, 2009, Pages 2256-2272

  Ancizu, Saioa ^a   Moreno, Elsa ^a   Torres, Enrique ^a   Burguete, Asunción ^a   Pérez Silanes, Silvia ^a   Benítez, Diego ^b   Villar, Raquel ^a   Solano, Beatriz ^a   Marín, Adoración ^a   Aldana, Ignacio ^a   Cerecetto, Hugo ^b   González, Mercedes ^b   Monge, Antonio ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

Mycobacterium tuberculosis; Neglected diseases; Quinoxaline; Trypanosoma cruzi

Indexed keywords

QUINOXALINE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TRYPANOSOMA;

ANIMALS; ANTITUBERCULAR AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; QUINOXALINES; RIFAMPIN; TRYPANOSOMA;

EID: 68949216306     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules14062256     Document Type: Article

References (30)

1. TAACF: http://www.taacf.org/about-TB-background.htm. Accessed May 5, 2009.
2. NIAID: http://www3.niaid.nih.gov/topics/tuberculosis/. Accessed May 5, 2009.
3. Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents. J. Med. Chem. 2005, 48, 2019-2025.
4. Tangallapally, R.P.; Yendapally, R.; Lee, R.E.; Hevener, K.; Jones, V.C.; Lenaerts, A.J.; McNeil, M.R.; Wang, Y.; Franzblau, S.; Lee, R.E. Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents. J. Med. Chem. 2004, 47, 5276-5283.
5. WHO: http://www.who.int/neglected_diseases/diseases/chagas/en/index.html. Accessed June 14, 2009.
6. Cerecetto, H.; González, M. Chemotherapy of Chagas´ disease: Status and new developments. Curr. Top. Med. Chem. 2002. 2, 1187-1213.
7. González, M.; Cerecetto, H.; Monge, A. Quinoxaline 1,4-dioxide and Phenazine 5,10-dioxide. Chemistry and Biology. In Topics in Heterocyclic Chemistry. Bioactive Heterocycles V; Khan, M.T.H., Ed.; Springer: Berlin, Germany, 2007; Volume 11, p. 179-211.
8. Ortega, M.A.; Sainz, Y.; Montoya, M.E.; López de Ceráin, A.; Monge, A. Synthesis and antituberculosis activity of new 2-quinoxalinecarbonitrile 1,4-di-N-oxides. Pharmazie 1999, 54, 24-25.
9. Sainz, Y.; Montoya, M.E.; Martínez-Crespo, F.J.; Ortega, M.A.; López de Ceráin, A.; Monge, A. New quinoxaline 1,4-di-N-oxides for treatment of tuberculosis. Arzneimittelforschung 1999, 49, 55-59.
10. Ortega, M.A.; Montoya, M.E.; Jaso, A.; Zarranz, B.; Tirapu, I.; Aldana, I.; Monge, A. Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. Pharmazie 2001, 56, 205-207.
11. Ortega, M.A.; Sainz, Y.; Montoya, M.E.; Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. Anti-Mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2carbonitrile 1,4-di-N-oxide. Arzneimittelforschung 2002, 52, 113-119.
12. Zarranz, B.; Jaso, A.; Aldana, I.; Monge, A. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. Bioorg. Med. Chem. 2003, 11, 2149-2156.
13. Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Eur. J. Med. Chem. 2003, 38, 791-800.
14. Villar, R.; Vicente, E.; Solano, B.; Pérez-Silanes, S.; Aldana, I.; Maddry, J.A.; Lenaerts, A.J.; Franzblau, S.G.; Cho, S.H.; Monge, A.; Goldman, R.C. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J. Antimicrob. Chemother. 2008, 62, 547-554.
15. Vicente, E.; Villar, R.; Burguete, A.; Solano, B.; Pérez-Silanes, S.; Aldana, I.; Maddry, J.A.; Lenaerts, A.J.; Franzblau, S.G.; Cho, S.H.; Monge, A.; Goldman, R.C. Efficacy of quinoxaline-2carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis. Antimicrob. Agents Chemother. 2008, 52, 3321-3326.
16. Vicente, E.; Pérez-Silanes, S.; Lima, L.M.; Ancizu, S.; Burguete, A.; Solano, B.; Villar, R.; Aldana, I.; Monge, A. Selective activity against Mycobacterium tuberculosis of new quinoxaline 1,4-di-N-oxides. Bioorg. Med. Chem. 2009, 17, 385-389.
17. Aguirre, G.; Cerecetto, H.; Di Maio, R.; González, M.; Montoya Alfaro, M.E.; Jaso, A.; Zarranz, B.; Ortega, M.A.; Aldana, I.; Monge-Vega, A. Quinoxaline N,N'-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships. Bioorg. Med. Chem. Lett. 2004, 14, 3835-3839.
18. Lavaggi, M.L.; Aguirre, G.; Boiani, L.; Orelli, L.; García, B.; Cerecetto, H.; González, M. Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Eur. J. Med. Chem. 2008 43, 1737-1741.
19. Vicente, E.; Duchowicz, P.R.; Castro, E.A.; Monge, A. QSAR analysis for quinoxaline-2carboxylate 1,4-di-N-oxides as anti-mycobacterial agents. J. Mol. Graph. Model. 2009, doi:10.1016/j.jmgm.2009.03.004.
20. Vicente, E.; Villar, R.; Burguete, A.; Solano, B.; Ancizu, S.; Pérez-Silanes, S.; Aldana, I.; Monge, A. Substitutions of fluorine atoms and phenoxy groups in the synthesis of quinoxaline 1,4-di-N-oxide derivatives. Molecules 2008, 13, 86-95.
21. Cerecetto, H.; González, M. Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds. Mini Rev. Med. Chem. 2008, 8, 1355-1383.
22. González, M.; Cerecetto, H. Benzofuroxan and Furoxan. Chemistry and Biology. In Topics in Heterocyclic Chemistry. Bioactive Heterocycles V.; Khan, M.T.H, Ed.; Springer: Berlin, Germany, 2007; Volume 10, pp. 265-308.
23. Ley, K.; Seng. F. Synthesis unter verwendung von benzofuroxan. Synthesis 1975, 415-422.
24. Dellaria, J.F.; Sallin K.J.; Rodriques, K. Synthesis of new amide-linked N-hydroxyurea 5-lipoxygenase inhibitors by an intramolecular oxygen to nitrogen acyl transfer. Bioorg. Med. Chem. Lett. 1993, 3, 305-308.
25. Cheeseman G.W.H.; Cookson, R.F. In Condensed Pyrazines. Wiley and Sons: New York, NY, USA, 1979; p. 35.
26. TAACF: http://www.taacf.org/Process-text.htm#assays. Accessed 5 May, 2009.
27. Collins, L.A.; Franzblau, S.G. Microplate Alamar Blue Assay versus BACTEC 460 System for High-Throughput Screening of Compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Antimicrob. Agents Chemother. 1997, 41, 1004-1009.
28. Porcal, W.; Hernández, P.; Boiani, M.; Aguirre, G.; Boiani, L.; Chidichimo, A.; Cazzulo, J.J.; Campillo, N.E.; Paez, J.A.; Castro, A.; Krauth-Siegel, R.L.; Davies, C.; Basombrío, M.A.; González, M.; Cerecetto, H. In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives. J. Med. Chem. 2007, 50, 6004-6015.
29. Rodríguez, J.; Gerpe, A.; Aguirre, G.; Kemmerling, U.; Piro, O.E.; Arán, V.J.; Maya, J.D.; Olea-Azar, C.; González, M.; Cerecetto, H. Study of 5-nitroindazoles' anti-Trypanosoma cruzi mode of action: electrochemical behaviour and ESR spectroscopic studies. Eur. J. Med. Chem. 2009, 44, 1545-1553.
30. Bollini, M.; Casal, J.J.; Alvarez, D.E.; Boiani, L.; González, M.; Cerecetto, H.; Bruno, A.M. New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships. Bioorg. Med. Chem. 2009, 17, 1437-1444.